Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 74Carcinoma, Non-Small-Cell Lung 73Breast Neoplasms 39Lung Neoplasms 31Urinary Bladder Neoplasms 28Nasopharyngeal Carcinoma 28Ovarian Neoplasms 25Neoplasm Metastasis 21Cholangiocarcinoma 18Triple Negative Breast Neoplasms 16Neoplasms 16Lymphoma, Large B-Cell, Diffuse 13Gallbladder Neoplasms 13Biliary Tract Neoplasms 13Uterine Cervical Neoplasms 12Recurrence 12Carcinoma, Transitional Cell 12Nasopharyngeal Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Fallopian Tube Neoplasms 10Non-Muscle Invasive Bladder Neoplasms 9Lymphoma 7Carcinoma 7Bile Duct Neoplasms 7Lymphoma, Non-Hodgkin 6Adenocarcinoma 6Carcinoma, Hepatocellular 5Adenocarcinoma of Lung 5Neoplasms by Site 4Urothelial Cancer 3

Interventions

Cisplatin 8Radiotherapy 5Paclitaxel 5Docetaxel 5Cetuximab 4Carboplatin 4pembrolizumab 3figitumumab 2cemiplimab 2advexin 2Radiation 2Methotrexate 2Fluorouracil 2Drug Therapy 2Bleomycin 2vandetanib 1talimogene laherparepvec 1sintilimab 1nedaplatin 1nanocis 1methyl 5-aminolevulinate 1ficlatuzumab 1dusquetide 1brigatinib 1avasopasem manganese 1alpha-2'-deoxythioguanosine 1Vinorelbine 1Tretinoin 1Tirapazamine 1Technetium-99 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Squamous Cell × Gemcitabine × Clear all
NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Maia Biotechnology

Phase 3 Recruiting
300 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡